CAV1 and metabolic dysfunction-associated steatotic liver disease: In our study, CAV1 function was supplemented by intraperitoneally injecting CSD, which effectively reversed cholesterol accumulation, ER stress, and pyroptosis exacerbated by CAV1 deficiency; thus, slowing the progression of MASLD.